Search - tctmd.com

Displaying 721 - 740 of 883

Sort: Relevancy | Date

Presentation TCT 2016

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Assessment and Critical Appraisal of Ongoing RDN Studies: Will the Results Accurately Reflect RDN Effectiveness?

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Justin E. Davies

October 30, 2016

Presentation TCT 2016

Alcohol Chemical Neurolysis (Ablative Solutions): Peregrine Results and the Sham-controlled TARGET BP I Trial

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, David E. Kandzari

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Kona WAVE IV Trial

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Roland E Schmieder

October 30, 2016

Presentation TCT 2016

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Presenter: Mayank Yadav

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Recor RADIANCE HTN Study

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Laura Mauri

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: St. Jude's EnligHTN Program

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, William B. White

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Medtronic GLOBAL SYMPLICITY SPYRAL HTN Trial Program

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, David E. Kandzari

October 30, 2016

Presentation TCT 2016

Device Overview and Ongoing Study Design: Boston Scientific REINFORCE

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Ajay J. Kirtane

October 30, 2016

Presentation TCT 2016

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Bryan Williams

October 30, 2016

Presentation TCT 2016

Overcoming RDN Catheter Design Limitations: Issues and Spectrum of Devices

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Horst Sievert

October 30, 2016

Presentation TCT 2016

Renal Denervation for Hypertension: New Insights and A Progress Report From Last Year

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Felix Mahfoud

October 30, 2016

Presentation TCT 2016

Hypertension Treatment Targets Beyond the Kidneys

Presenter: Felix Mahfoud, Michael A. Weber, Atul Pathak

October 30, 2016

Presentation TCT 2016

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Presenter: Felix Mahfoud, Michael A. Weber, Michael Joner

October 30, 2016

Presentation TCT 2016

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Presenter: Felix Mahfoud, Michael A. Weber, Ehtisham Mahmud

October 30, 2016

Presentation TCT 2016

Whats Next for the Nurse/Tech Team?

Presenter: Regina Deible, Mary K. Egan

October 30, 2016

Presentation TCT 2016

Implications of Recent Hypertension Studies for Optimal BP Targets and Clinical Practice (SPRINT, PATHWAYS, Others)

Presenter: Felix Mahfoud, Michael A. Weber

October 30, 2016

Presentation TCT 2016

Evolution of the Nurse/Tech Role in the Cath Lab

Presenter: Regina Deible, Mary K. Egan

October 30, 2016

Presentation TCT 2016

Personalized Medicine Where Are We in 2016?

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Anti-inflammatory Therapies for Atherosclerosis

Presenter: Robert A. Harrington, A. Michael Lincoff, Jean-Claude Tardif

October 30, 2016

Advertisement

Why are These Trials Recruiting Slowly and How Can We Improve Recruitment Rates?

Assessment and Critical Appraisal of Ongoing RDN Studies: Will the Results Accurately Reflect RDN Effectiveness?

Alcohol Chemical Neurolysis (Ablative Solutions): Peregrine Results and the Sham-controlled TARGET BP I Trial

Device Overview and Ongoing Study Design: Kona WAVE IV Trial

The Smoker's Paradox Revisited: A Five-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials

Device Overview and Ongoing Study Design: Recor RADIANCE HTN Study

Device Overview and Ongoing Study Design: St. Jude's EnligHTN Program

Device Overview and Ongoing Study Design: Medtronic GLOBAL SYMPLICITY SPYRAL HTN Trial Program

Device Overview and Ongoing Study Design: Boston Scientific REINFORCE

Overcoming Clinical Design Issues: What to Look for (and Demand) in Ongoing and Future Hypertension Device Trials

Overcoming RDN Catheter Design Limitations: Issues and Spectrum of Devices

Renal Denervation for Hypertension: New Insights and A Progress Report From Last Year

Hypertension Treatment Targets Beyond the Kidneys

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Whats Next for the Nurse/Tech Team?

Implications of Recent Hypertension Studies for Optimal BP Targets and Clinical Practice (SPRINT, PATHWAYS, Others)

Evolution of the Nurse/Tech Role in the Cath Lab

Personalized Medicine Where Are We in 2016?

Anti-inflammatory Therapies for Atherosclerosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content